William S. Aronstein

Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study

Piotr Krzeski, Chris Buckland‐Wright, Géza Bálint et al. · Arthritis Research & Therapy · 2007 · 203 citations · Full text

Medicine, Orthopaedic Surgery, Pharmacology +9

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis

Stephen A. Harrison, Sheetal Marri, Naga Chalasani et al. · Alimentary Pharmacology & Therapeutics · 2016 · 172 citations

Medicine, Pharmacology, Pharmacotherapy +17

Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial

Patrick Garnero, William S. Aronstein, Stanley Cohen et al. · Osteoarthritis and Cartilage · 2007 · 86 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +16

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Zelalem Temesgen, Charles D. Burger, Jason Baker et al. · The Lancet Respiratory Medicine · 2021 · 74 citations · Full text

Pharmacy, Infectious Diseases, Internal Medicine +13

Molecular identity of a major antigen of<i>Schistosoma mansoni</i>which cross-reacts with<i>Trichinella spiralis</i>and<i>Fasciola hepatica</i>

William S. Aronstein, Samuel A. Lewis, Amy P. Norden et al. · Parasitology · 1986 · 42 citations

Veterinary Medicine, Immunology, Infectious Diseases +16